NCT07104929已完成2 期
Prospective Human Study Evaluating the Effects of Beta Glucan 500 on Markers of Biological Age and Immune Age: An Open-label Pilot Study
OvationLab1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年5月14日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Epigenetic Testing
研究概览
简要总结
The primary purpose of this study is to evaluate the effects of BWH Labs - Beta Glucan 500 on biomarkers of biological and immune age among healthy adults.
A single-arm, open-label prospective study will be conducted evaluating the impact of 12 weeks of supplementation with two capsules daily of Beta Glucan 500 on a variety of validated markers of biological and immune age on the comprehensive TruAge panel (TruDiagnostics, Lexington, KY).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult females or males age ≥ 40 years
- •Ability to read and speak English
- •Previous completion of a TruDiagnostic TruAge test within the past three months to enable comparison of previous biomarkers to the same biomarkers after intervention
- •DunedinPACE estimate of aging >0.9
排除标准
- •Current diagnosis and treatment for an autoimmune condition
- •Current use of beta-glucan or mushroom dietary supplement
- •Known allergies to beta glucan, yeast, or mushrooms
- •Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
- •Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
- •Participants unable to provide consent
研究组 & 干预措施
Beta Glucan
Experimental
干预措施: Beta Glucan (Dietary Supplement)
结局指标
主要结局
Epigenetic Testing
时间窗: Change from baseline to 12 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A Clinical Study to Determine if Beta Glucan Reduces the Incidence, Duration or Severity of URTIs Among SkiersUpper Respiratory Tract InfectionsMental StressNCT05917015USANA Health Sciences45
已完成
1 期
Effect of SBG in Patients With Breast CancerBreast CancerNCT00533364Biotec Pharmacon ASA11
已完成
1 期
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00533728Biotec Pharmacon ASA12
已完成
2 期
Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.HyperlipidemiasNCT03857256Montreal Heart Institute263
已完成
3 期
Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot UlcersChronic Diabetic Foot UlcersNCT00632008Biotec Pharmacon ASA122